3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF
申请人:ALLERGAN, INC.
公开号:US20190047947A1
公开(公告)日:2019-02-14
Described herein are compounds, or pharmaceutically acceptable salts thereof, of the following formula:
The compounds are useful for treating inflammatory and autoimmune diseases.
本文描述了以下结构的化合物或其药用盐:
这些化合物可用于治疗炎症性和自身免疫性疾病。
3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof
申请人:ALLERGAN, INC.
公开号:US11208377B2
公开(公告)日:2021-12-28
Described herein are compounds, or pharmaceutically acceptable salts thereof, of the following formula:
The compounds are useful for treating inflammatory and autoimmune diseases.
本文描述的是下式化合物或其药学上可接受的盐类:
这些化合物可用于治疗炎症和自身免疫性疾病。
OXADIAZOLE AMINE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
申请人:Chong Kun Dang Pharmaceutical Corp.
公开号:EP3362445A1
公开(公告)日:2018-08-22
[EN] OXADIAZOLE AMINE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME<br/>[FR] COMPOSÉS DÉRIVÉS D'OXADIAZOLE AMINE UTILISÉS EN TANT QU'INHIBITEUR DE L'HISTONE DÉSACÉTYLASE 6, ET COMPOSITION PHARMACEUTIQUE LES COMPRENANT
申请人:CHONG KUN DANG PHARMACEUTICAL CORP
公开号:WO2017065473A1
公开(公告)日:2017-04-20
The present disclosure relates to novel compounds having histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. The novel compounds, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present disclosure have histone deacetylase (HDAC) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases, including infectious diseases; neoplasms; endocrine, nutritional and metabolic diseases; mental and behavioral disorders; neurological diseases; diseases of the eye and adnexa; cardiovascular diseases; respiratory diseases; digestive diseases; diseases of the skin and subcutaneous tissue; diseases of the musculoskeletal system and connective tissue; or congenital malformations, deformations and chromosomal abnormalities.